Adjuvant therapy of biliary tract cancers
Standard
Adjuvant therapy of biliary tract cancers. / Kefas, Joanna; Bridgewater, John; Vogel, Arndt; Stein, Alexander; Primrose, John.
in: THER ADV MED ONCOL, Jahrgang 15, 2023, S. 17588359231163785.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Transfer
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Adjuvant therapy of biliary tract cancers
AU - Kefas, Joanna
AU - Bridgewater, John
AU - Vogel, Arndt
AU - Stein, Alexander
AU - Primrose, John
N1 - © The Author(s), 2023.
PY - 2023
Y1 - 2023
N2 - Biliary tract cancers (BTCs) are rare and heterogeneous malignant tumours including cholangiocarcinoma and gallbladder cancer. They are very aggressive, often refractory to chemotherapy and associated with an overall poor prognosis. Surgical resection remains the only potentially curative treatment option but less than 35% present with resectable disease. Adjuvant treatments have been widely used but until recently, supportive data were limited to non-randomised, non-controlled retrospective studies. Recent evidence from the BILCAP trial has established adjuvant capecitabine as the standard of care. But there are still unanswered questions as to the role of adjuvant therapy. Further prospective data and translational research with reproducible evidence of clinical benefit are needed. In this review of adjuvant therapy in resectable BTCs, we will summarise the latest evidence setting current treatment standards and highlight future prospects.
AB - Biliary tract cancers (BTCs) are rare and heterogeneous malignant tumours including cholangiocarcinoma and gallbladder cancer. They are very aggressive, often refractory to chemotherapy and associated with an overall poor prognosis. Surgical resection remains the only potentially curative treatment option but less than 35% present with resectable disease. Adjuvant treatments have been widely used but until recently, supportive data were limited to non-randomised, non-controlled retrospective studies. Recent evidence from the BILCAP trial has established adjuvant capecitabine as the standard of care. But there are still unanswered questions as to the role of adjuvant therapy. Further prospective data and translational research with reproducible evidence of clinical benefit are needed. In this review of adjuvant therapy in resectable BTCs, we will summarise the latest evidence setting current treatment standards and highlight future prospects.
U2 - 10.1177/17588359231163785
DO - 10.1177/17588359231163785
M3 - SCORING: Review article
C2 - 37007632
VL - 15
SP - 17588359231163785
JO - THER ADV MED ONCOL
JF - THER ADV MED ONCOL
SN - 1758-8340
ER -
